首页 > 市场调查报告书 > 製药

医药品原料药

市场调查报告书

商品编码

1609657

2025-2033 年日本活性药物成分市场报告（按药物类型、製造商类型、合成类型、治疗应用和地区）

Japan Active Pharmaceutical Ingredients Market Report by Drug Type, Type of Manufacturer, Type of Synthesis, Therapeutic Application, and Region 2025-2033

出版日期: 2024年12月05日 | 出版商:

IMARC | 英文 118 Pages | 商品交期: 5-7个工作天内

价格

简介目录

2024 年日本活性药物成分 (API) 市场IMARC Group达到 279 亿美元。对生物相似药和仿製药的需求不断增加，加上临床试验数量不断增加，主要推动了市场的成长。

活性药物成分 (API) 是药物的重要组成部分，可确保它们达到预期的治疗效果。这些生物活性化合物对于治疗和控制许多健康问题的症状至关重要。它们是透过复杂的化学和生物方法製成的，其纯度、强度和一致性对其药效至关重要。 API 可以对多种疾病进行特定治疗，使製药公司能够针对特定疾病和人群开发适合的药物。它们被纳入各种药物形式，如丸剂、胶囊、乳膏或註射剂，每种形式都有独特的製造需求。与此一致，活性药物成分有助于药物传递技术的进步，增强药物在人体内的有效和安全的分散。

日本活性药物成分 (API) 市场趋势：

日本的活性药物成分市场正在大幅增长，这主要是由其製药领域的指数级发展所推动的。随着日本努力应对各种慢性病日益流行的问题，对 API 的需求不断增加，这反映了新兴趋势。推动日本这一市场轨蹟的一个显着因素是其製药巨头的深入研究和开发工作。此外，他们寻求推出增强型产品迭代，特别是高效活性药物成分，为国家原料药市场描绘了一幅乐观的图景。除此之外，日本製药业在全球健康危机期间取得的前所未有的进展进一步放大了该市场的势头。同时，日本作为技术发展的热点，正在生物技术和生命科学领域取得突破，这些因素正在塑造其 API 格局。研究机构数量的增加和临床探索的增加预示着成长潜力。再加上城市的快速扩张、日本老年人口的迅速增长以及政府和私人实体为完善医疗基础设施而进行的大量投资，显然日本的活性药物成分市场在可预见的未来将持续增长。

日本活性药物成分 (API) 市场细分：

药物类型见解：

创新活性药物成分（API）
仿製药活性成分 (API)

製造商洞察类型：

专属製造商
商家 API 製造商
创新商业 API 製造商
通用商家 API 製造商

综合见解的类型：

合成活性药物成分 (API)
类型
创新的合成原料药
通用合成 API
生物技术活性药物成分 (API)
类型
创新生物技术 API
生物相似药
产品
单株抗体
疫苗
细胞因子
融合蛋白
治疗酵素
血液因素
表达系统
哺乳动物表达系统
微生物表现系统
酵母表现系统
基因改造动物系统
其他的

治疗应用见解：

肿瘤学
心血管和呼吸系统
糖尿病
中枢神经系统疾病
神经系统疾病
其他的

竞争格局：

市场研究报告也对市场竞争格局进行了全面分析。报告涵盖了市场结构、关键参与者定位、最佳制胜策略、竞争仪表板和公司评估象限等竞争分析。此外，也提供了所有主要公司的详细资料。

本报告回答的关键问题：

日本活性药物成分 (API) 市场迄今表现如何，未来几年又将如何表现？
COVID-19 对日本活性药物成分 (API) 市场有何影响？
日本活性药物成分 (API) 市场按药物类型划分是怎样的？
日本活性药物成分 (API) 市场按製造商类型划分是怎样的？
日本活性药物成分 (API) 市场以合成类型划分是怎样的？
日本活性药物成分 (API) 市场在治疗应用方面的细分情况如何？
日本活性药物成分（API）市场价值链的各个阶段是什么？
日本活性药物成分（API）的关键驱动因素和挑战是什么？
日本活性药物成分 (API) 市场的结构如何？
日本原料药（API）市场的竞争程度如何？

本报告回答的关键问题：

日本活性药物成分 (API) 市场迄今表现如何，未来几年又将如何表现？
COVID-19 对日本活性药物成分 (API) 市场有何影响？
日本活性药物成分 (API) 市场按药物类型划分是怎样的？
日本活性药物成分 (API) 市场按製造商类型划分是怎样的？
日本活性药物成分 (API) 市场以合成类型划分是怎样的？
日本活性药物成分 (API) 市场在治疗应用方面的细分情况如何？
日本活性药物成分（API）市场价值链的各个阶段是什么？
日本活性药物成分（API）的关键驱动因素和挑战是什么？
日本活性药物成分 (API) 市场的结构如何？
日本原料药（API）市场的竞争程度如何？

合成活性药物成分 (API)
- 概述
- 历史与当前市场趋势（2019-2024）
- 市场区隔
  - 类型
    - 创新的合成原料药
    - 通用合成 API
- 市场预测（2025-2033）
生物技术活性药物成分 (API)
- 概述
- 历史与当前市场趋势（2019-2024）
- 市场区隔
  - 类型
    - 创新生物技术 API
    - 生物相似药
  - 产品
    - 单株抗体
    - 疫苗
    - 细胞因子
    - 融合蛋白
    - 治疗酵素
    - 血液因素
  - 表达系统
    - 哺乳动物表达系统
    - 微生物表现系统
    - 酵母表现系统
    - 基因改造动物系统
    - 其他的
- 市场预测（2025-2033）

第 9 章：日本活性药物成分 (API) 市场 - 细分：按治疗应用分类

肿瘤学
- 概述
- 历史与当前市场趋势（2019-2024）
- 市场预测（2025-2033）
心血管和呼吸系统
- 概述
- 历史与当前市场趋势（2019-2024）
- 市场预测（2025-2033）
糖尿病
- 概述
- 历史与当前市场趋势（2019-2024）
- 市场预测（2025-2033）
中枢神经系统疾病
- 概述
- 历史与当前市场趋势（2019-2024）
- 市场预测（2025-2033）
神经系统疾病
- 概述
- 历史与当前市场趋势（2019-2024）
- 市场预测（2025-2033）
其他的
- 历史与当前市场趋势（2019-2024）
- 市场预测（2025-2033）

第 10 章：日本活性药物成分 (API) 市场 - 竞争格局

概述
市场结构
市场参与者定位
最佳制胜策略
竞争仪表板
公司评估象限

第 11 章：关键参与者简介

Company A

Business Overview
Product Portfolio
Business Strategies
SWOT Analysis
Major News and Events

Company B

Business Overview
Product Portfolio
Business Strategies
SWOT Analysis
Major News and Events

Company C

Business Overview
Product Portfolio
Business Strategies
SWOT Analysis
Major News and Events

Company D

Business Overview
Product Portfolio
Business Strategies
SWOT Analysis
Major News and Events

Company E

Business Overview
Product Portfolio
Business Strategies
SWOT Analysis
Major News and Events

第 12 章：日本活性药物成分 (API) 市场 - 产业分析

驱动因素、限制因素和机会
- 概述
- 司机
- 限制
- 机会
波特五力分析
- 概述
- 买家的议价能力
- 供应商的议价能力
- 竞争程度
- 新进入者的威胁
- 替代品的威胁
价值链分析

第 13 章：附录

简介目录

Product Code: SR112024A16298

Japan active pharmaceutical ingredients (API) market size reached USD 27.9 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 43.2 Billion by 2033, exhibiting a growth rate (CAGR) of 5% during 2025-2033. The increasing need for biosimilars and generic drugs, coupled with the growing number of clinical trials, is primarily driving the market growth.

Active pharmaceutical ingredients (APIs) are essential components of medications, ensuring they deliver the desired healing outcomes. These biologically active compounds are vital in treating and managing symptoms of numerous health issues. They are crafted through intricate chemical and biological methodologies, with their purity, strength, and consistency being critical for their medicinal efficacy. APIs enable specific treatments for a wide range of illnesses, allowing pharmaceutical companies to create drugs tailored to specific diseases and populations. They are incorporated in various drug formats, such as pills, capsules, creams, or injections, each with unique manufacturing needs. In line with this, active pharmaceutical ingredients contribute to the progression of drug delivery techniques, enhancing the efficient and safe dispersion of drugs within the human body.

Japan Active Pharmaceutical Ingredients (API) Market Trends:

The active pharmaceutical ingredients market in Japan is witnessing substantial growth, driven predominantly by the exponential progression in its pharmaceutical domain. As Japan grapples with a rising prevalence of various chronic ailments, there's a heightened demand for APIs, mirroring emerging trends. A notable factor propelling this market trajectory in Japan is the intensive research and development endeavors by its pharmaceutical giants. Additionally, their quest to launch enhanced product iterations, especially high-potency active pharmaceutical ingredients, paints an optimistic picture for the nation's API market. Besides this, the unprecedented strides taken by the Japanese pharmaceutical sector during global health crises further amplify this market's momentum. Concurrently, Japan, being a hotspot of technological evolution, is experiencing breakthroughs in biotechnology and life sciences, factors that are auspiciously shaping its API landscape. An augmented count of research institutions and the uptick in clinical explorations signify the growth potential. Compounded by the rapid urban sprawl, Japan's burgeoning elderly demographic, and substantial investments by both governmental and private entities towards refining the healthcare infrastructure, it's evident that Japan's active pharmaceutical ingredients market is poised for sustained growth in the foreseeable future.

Japan Active Pharmaceutical Ingredients (API) Market Segmentation:

Drug Type Insights:

Innovative Active Pharmaceutical Ingredients (API)
Generic Active Pharmaceutical Ingredients (API)

Type of Manufacturer Insights:

Captive Manufacturers
Merchant API Manufacturers
Innovative Merchant API Manufacturers
Generic Merchant API Manufacturers

Type of Synthesis Insights:

Synthetic Active Pharmaceutical Ingredients (API)
Type
Innovative Synthetic APIs
Generic Synthetic APIs
Biotech Active Pharmaceutical Ingredients (API)
Type
Innovative Biotech APIs
Biosimilars
Product
Monoclonal Antibodies
Vaccines
Cytokines
Fusion Proteins
Therapeutic Enzymes
Blood Factors
Expression System
Mammalian Expression Systems
Microbial Expression Systems
Yeast Expression Systems
Transgenic Animal Systems
Others

Therapeutic Application Insights:

Oncology
Cardiovascular and Respiratory
Diabetes
Central Nervous System Disorders
Neurological Disorders
Others

Competitive Landscape:

The market research report has also provided a comprehensive analysis of the competitive landscape in the market. Competitive analysis such as market structure, key player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided.

Key Questions Answered in This Report:

How has the Japan active pharmaceutical ingredients (API) market performed so far and how will it perform in the coming years?
What has been the impact of COVID-19 on the Japan active pharmaceutical ingredients (API) market?
What is the breakup of the Japan active pharmaceutical ingredients (API) market on the basis of drug type?
What is the breakup of the Japan active pharmaceutical ingredients (API) market on the basis of type of manufacturer?
What is the breakup of the Japan active pharmaceutical ingredients (API) market on the basis of type of synthesis?
What is the breakup of the Japan active pharmaceutical ingredients (API) market on the basis of therapeutic application?
What are the various stages in the value chain of the Japan active pharmaceutical ingredients (API) market?
What are the key driving factors and challenges in the Japan active pharmaceutical ingredients (API)?
What is the structure of the Japan active pharmaceutical ingredients (API) market and who are the key players?
What is the degree of competition in the Japan active pharmaceutical ingredients (API) market?

1 Preface

2 Scope and Methodology

2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Japan Active Pharmaceutical Ingredients (API) Market - Introduction

4.1 Overview
4.2 Market Dynamics
4.3 Industry Trends
4.4 Competitive Intelligence

5 Japan Active Pharmaceutical Ingredients (API) Market Landscape

5.1 Historical and Current Market Trends (2019-2024)
5.2 Market Forecast (2025-2033)

6 Japan Active Pharmaceutical Ingredients (API) Market - Breakup by Drug Type

6.1 Innovative Active Pharmaceutical Ingredients (API)
- 6.1.1 Overview
- 6.1.2 Historical and Current Market Trends (2019-2024)
- 6.1.3 Market Forecast (2025-2033)
6.2 Generic Active Pharmaceutical Ingredients (API)
- 6.2.1 Overview
- 6.2.2 Historical and Current Market Trends (2019-2024)
- 6.2.3 Market Forecast (2025-2033)

7 Japan Active Pharmaceutical Ingredients (API) Market - Breakup by Type of Manufacturer

7.1 Captive Manufacturers
- 7.1.1 Overview
- 7.1.2 Historical and Current Market Trends (2019-2024)
- 7.1.3 Market Forecast (2025-2033)
7.2 Merchant API Manufacturers
- 7.2.1 Overview
- 7.2.2 Historical and Current Market Trends (2019-2024)
- 7.2.3 Market Segmentation
  - 7.2.3.1 Innovative Merchant API Manufacturers
  - 7.2.3.2 Generic Merchant API Manufacturers
- 7.2.4 Market Forecast (2025-2033)

8 Japan Active Pharmaceutical Ingredients (API) Market - Breakup by Type of Synthesis

8.1 Synthetic Active Pharmaceutical Ingredients (API)
- 8.1.1 Overview
- 8.1.2 Historical and Current Market Trends (2019-2024)
- 8.1.3 Market Segmentation
  - 8.1.3.1 Type
    - 8.1.3.1.1 Innovative Synthetic APIs
    - 8.1.3.1.2 Generic Synthetic APIs
- 8.1.4 Market Forecast (2025-2033)
8.2 Biotech Active Pharmaceutical Ingredients (API)
- 8.2.1 Overview
- 8.2.2 Historical and Current Market Trends (2019-2024)
- 8.2.3 Market Segmentation
  - 8.2.3.1 Type
    - 8.2.3.1.1 Innovative Biotech APIs
    - 8.2.3.1.2 Biosimilars
  - 8.2.3.2 Product
    - 8.2.3.2.1 Monoclonal Antibodies
    - 8.2.3.2.2 Vaccines
    - 8.2.3.2.3 Cytokines
    - 8.2.3.2.4 Fusion Proteins
    - 8.2.3.2.5 Therapeutic Enzymes
    - 8.2.3.2.6 Blood Factors
  - 8.2.3.3 Expression System
    - 8.2.3.3.1 Mammalian Expression Systems
    - 8.2.3.3.2 Microbial Expression Systems
    - 8.2.3.3.3 Yeast Expression Systems
    - 8.2.3.3.4 Transgenic Animal Systems
    - 8.2.3.3.5 Others
- 8.2.4 Market Forecast (2025-2033)

9 Japan Active Pharmaceutical Ingredients (API) Market - Breakup by Therapeutic Application

9.1 Oncology
- 9.1.1 Overview
- 9.1.2 Historical and Current Market Trends (2019-2024)
- 9.1.3 Market Forecast (2025-2033)
9.2 Cardiovascular and Respiratory
- 9.2.1 Overview
- 9.2.2 Historical and Current Market Trends (2019-2024)
- 9.2.3 Market Forecast (2025-2033)
9.3 Diabetes
- 9.3.1 Overview
- 9.3.2 Historical and Current Market Trends (2019-2024)
- 9.3.3 Market Forecast (2025-2033)
9.4 Central Nervous System Disorders
- 9.4.1 Overview
- 9.4.2 Historical and Current Market Trends (2019-2024)
- 9.4.3 Market Forecast (2025-2033)
9.5 Neurological Disorders
- 9.5.1 Overview
- 9.5.2 Historical and Current Market Trends (2019-2024)
- 9.5.3 Market Forecast (2025-2033)
9.6 Others
- 9.6.1 Historical and Current Market Trends (2019-2024)
- 9.6.2 Market Forecast (2025-2033)

10 Japan Active Pharmaceutical Ingredients (API) Market - Competitive Landscape

10.1 Overview
10.2 Market Structure
10.3 Market Player Positioning
10.4 Top Winning Strategies
10.5 Competitive Dashboard
10.6 Company Evaluation Quadrant

11 Profiles of Key Players

11.1 Company A
- 11.1.1 Business Overview
- 11.1.2 Product Portfolio
- 11.1.3 Business Strategies
- 11.1.4 SWOT Analysis
- 11.1.5 Major News and Events
11.2 Company B
- 11.2.1 Business Overview
- 11.2.2 Product Portfolio
- 11.2.3 Business Strategies
- 11.2.4 SWOT Analysis
- 11.2.5 Major News and Events
11.3 Company C
- 11.3.1 Business Overview
- 11.3.2 Product Portfolio
- 11.3.3 Business Strategies
- 11.3.4 SWOT Analysis
- 11.3.5 Major News and Events
11.4 Company D
- 11.4.1 Business Overview
- 11.4.2 Product Portfolio
- 11.4.3 Business Strategies
- 11.4.4 SWOT Analysis
- 11.4.5 Major News and Events
11.5 Company E
- 11.5.1 Business Overview
- 11.5.2 Product Portfolio
- 11.5.3 Business Strategies
- 11.5.4 SWOT Analysis
- 11.5.5 Major News and Events

12 Japan Active Pharmaceutical Ingredients (API) Market - Industry Analysis

12.1 Drivers, Restraints, and Opportunities
- 12.1.1 Overview
- 12.1.2 Drivers
- 12.1.3 Restraints
- 12.1.4 Opportunities
12.2 Porters Five Forces Analysis
- 12.2.1 Overview
- 12.2.2 Bargaining Power of Buyers
- 12.2.3 Bargaining Power of Suppliers
- 12.2.4 Degree of Competition
- 12.2.5 Threat of New Entrants
- 12.2.6 Threat of Substitutes
12.3 Value Chain Analysis